<DOC>
	<DOCNO>NCT01626976</DOCNO>
	<brief_summary>This first-in-human study oral investigational compound , PF-06282999 , order ass safety , tolerability pharmacokinetics human across wide range dose level .</brief_summary>
	<brief_title>A Study To Assess The Safety , Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Women must nonchildbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include clinically significant drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose study medication . As exception , acetaminophen/paracetamol may use dos â‰¤1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>oral</keyword>
	<keyword>single ascend dose</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>healthy subject</keyword>
</DOC>